| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Chances of Entera Bio to slide after the volatility rises
 | By Vlad Skutelnik | Macroaxis Story |
Lets try to break down the odds of Entera Bio to fully recover from the current slide as its shares went up 0.90%. Entera Bio's current daily volatility is 4.78 percent, with a beta of -0.11 and an alpha of -0.28 over DOW. While many traders are getting carried away by overanalyzing pharmaceutical products, it is reasonable to break down Entera Bio. We will evaluate if Entera Bio shares are reasonably priced going into December.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
Entera Bio currently holds roughly 9.77 M in cash with (11.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.54. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Entera Bio has an asset utilization ratio of 2.7 percent. This suggests that the company is making $0.027 for each dollar of assets. An increasing asset utilization means that Entera Bio is more efficient with each dollar of assets it utilizes for everyday operations.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Entera Bio. Your research has to be compared to or analyzed against Entera Bio's peers to derive any actionable benefits. When done correctly, Entera Bio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Entera Bio.
Investing in Entera Bio, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Entera Bio along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entera Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Entera Bio's Liquidity
Entera Bio financial leverage refers to using borrowed capital as a funding source to finance Entera Bio ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Entera Bio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Entera Bio's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Entera Bio's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Entera Bio's total debt and its cash.
Entera Bio Gross Profit
Entera Bio Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Entera Bio previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Entera Bio Gross Profit growth over the last 10 years. Please check Entera Bio's gross profit and other fundamental indicators for more details.
Entera Bio Correlation with Peers
Investors in Entera can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Entera Bio. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Entera Bio and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Entera is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Entera for more details
Detailed Perspective On Entera Bio
Entera Bio secures Sharpe Ratio (or Efficiency) of -0.0446, which denotes the company had -0.0446% of return per unit of risk over the last month. Macroaxis standpoint towards predicting the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Entera Bio exposes twenty-six different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Entera Bio coefficient of variation of (1,760), and Mean Deviation of 3.23 to check the risk estimate we provide.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Entera Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.